Many MSK staff favor Endnote as their citation management software. Saving an Endnote Library is one of the issues that requires special attention from the Endnote user.
In the desktop version of EndNote, a Library is saved with the extension .enl after its name, and its associated Data folder, with the extension .Data after its name. (NOTE: On Mac computers there is also an option to save your Library as a .enpl file, which combines both the library and the data file into one.)
The Library contains the records and the Data folder is intended for PDFs of the full text associated with the Endnote Library records, as well as anything inserted into the Image field of a reference. Even if no PDFs or images are available, the Data folder will still be there; however a Data folder should never be deleted. Data folders should never be moved or copied without first compressing them into a .enlx file. From there, the compressed zip file can be moved, copied, and shared.
It is important to know that saving an Endnote Library to any network drive does not work well. There is a very high chance of getting a pop-up Damaged Library message at some point if the Library is saved to any drive other than your local drive, i.e. to your computer. On a PC you may consider This PC>Documents for saving an Endnote Library. If you want to save a Library to a network drive for better security you can save a backup copy either as a Compressed Library as explained above or by using the Endnote File>Save a Copy feature. You can save the backup copy to your personal drive or, as a Read Only copy, to a shared drive for your collaborators’ use (but not for their adding/removing the content). As an alternative, instead of using a shared drive for sharing your Endnote Library with others, you can use the Endnote Online companion to your desktop Endnote for collaboration.
Don’t save an Endnote Library to a network drive.
Never delete the .Data folders associated with Endnote Libraries.
Don’t try moving the Library separately from its Data Folder, use the Compressed Library feature instead.
Emily Chenette, PhD, Editor-in-Chief, PLOS ONE Dr. Emily Chenette studied biochemistry at Columbia University as an undergraduate, and went on to earn her PhD in genetics and molecular biology from the University of North Carolina at Chapel Hill. She then completed postdoctoral research at Duke University, where she analysed gene expression signatures in lung cancer. Emily has always loved scientific writing and policy and left the bench to pursue an editorial career in 2007. Before joining PLOS ONE in 2018, she held editorial positions at Nature Cell Biology and The FEBS Journal.
Catherine Kyobutungi, MBChB, MSc, PhD, Editor-in-Chief, PLOS Global Public Health Dr. Catherine Kyobutungi is the Executive Director of the African Population and Health Research Center and co-Director of the Consortium for Advanced Research Training in Africa (CARTA) based in Nairobi, Kenya. Catherine has a medical background and is a trained epidemiologist with research interests in Non-Communicable Diseases and Health Systems Strengthening. She has designed and tested service delivery models for resource-constrained settings such as slum settings and is a strong advocate for the societal benefit of research beyond traditional research outputs. At APHRC, she has strengthened approaches to policy engagement and advocacy to ensure timely and effective uptake of evidence in decision making. She has more than 140 publications and sits on multiple national and global expert advisory panels.
Julia Robinson, MPH, MSW, Executive Editor, PLOS Global Public Health Julia Robinson studied history at Rice University before serving in the US Peace Corps in Benin, West Africa as a Rural Community Health Volunteer. Upon her return, she earned a Masters of Social Work and a Masters of Public Health at the University of Washington. Before joining PLOS ONE, Julia managed HIV programs and research in Cote d’Ivoire, West Africa and is active in global health policy and advocacy work. She joined PLOS in July 2020.
Food and Drug Administration (FDA) approval of two new advances promise to transform the detection of prostate cancer and the treatment of lung cancer.
On May 26, the FDA approved Pylarify, a molecule injected prior to positron emission tomography (PET) imaging that reveals prostate cancer cells on the scan. Pylarify does not replace prostate-specific antigen (PSA) screening, but will allow physicians to determine the extent of prostate cancer in patients suspected of having or diagnosed with the disease. Dr. Michael Morris led the phase III clinical trial at MSK. Read more from NBC News, Healio.com, and MSK.
On May 28, the FDA approved the use of sotorasib (Lumakras) in patients with advanced non-small cell lung cancer who have the KRAS-G12C genetic mutation and have already tried another treatment modality. This treatment was the culmination of almost 40 years of research, and was spearheaded through clinical trials by MSK’s Dr. Bob Li. Learn more from Good Morning America, TargetedOnc.com, and MSK.